Hospital Drug Survey: Ranmark And Lunesta On Top
This article was originally published in PharmAsia News
According to a Mix Online survey on medicine adopted by hospitals to compare the efficacy of old and new drugs, Daiichi Sankyo bone lesion drug Ranmark (denosumab) placed first and Eisai insomnia drug Lunesta (eszopiclone) placed second.
You may also be interested in...
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.